Outcome MeasureQuality of Life

WSAS

Work and Social Adjustment Scale

2 Papers in Blossom

Clinical Thresholds

040
Subclinical
Score 0–9
Significant impairment
Score 10–19
Moderately severe
Score 20–40

Outcome Data Across Studies

Reported results for WSAS across 1 study with quantitative data.

Outcome data across 2 study arm–timepoint observations
SD
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
2025Secondary
Psilocybin(experimental)-11227.0——
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
2025Secondary
Psilocybin(experimental)211217.9——

Papers Using WSAS

Open Accessindividual

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

This open-label trial (n=12) conducted at Sheppard Pratt Hospital finds that psilocybin (25mg) significantly decreases depressive symptoms in patients with severe treatment-resistant depression (TRD) at 3 weeks (MADRS −15.8) and 12 weeks (MADRS −17.2) post-treatment. Exploratory analyses suggest the Oceanic Boundlessness dimension correlates with antidepressant responses, while patients with comorbid PTSD show reduced antidepressant effects.

Published
Journal
American Journal of Psychiatry
Authors
Aaronson, S. T., Van Der Vaart, A., Miller, T., Lapratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., Sackeim, H. A.
Open Accessindividual

Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial

PsiDeR is a single-centre, randomised, placebo-controlled feasibility trial of psilocybin-assisted therapy in up to 60 people with treatment‑resistant major depressive disorder, testing a single 25 mg psilocybin dose plus psychological support with primary feasibility outcomes (recruitment, dropout and variance of the Montgomery–Åsberg Depression Rating Scale) at a 3‑week primary endpoint and 6‑week follow‑up. The protocol also collects optional neuroimaging and omics data for mechanism and biomarker analyses and offers an open‑label 25 mg psilocybin extension.

Published
Journal
BMJ Open
Authors
Rucker, J., Jafari, H., Mantingh, T., Bird, C., Modlin, N. L., Knight, G., Reinholdt, F., Day, C., Carter, B., Young, A.

Quick Facts

Full Name
Work and Social Adjustment Scale
Domain
Quality of Life
Papers Indexed
2
Score Range
0–40
Interpretation
Lower = better
All Measures